Get 40% Off
😲 Missed the +20.8% surge in our stock strategy last month? Not again! Get premium insightsGet 40% Off Now

Synageva BioPharma Corp (GEVA)

NASDAQ
Currency in USD
Disclaimer
238.60
0.00(0.00%)
Closed
Fair Value
Unlock Value
Day's Range
236.43239.20
52 wk Range
0.00239.20
Prev. Close
238.6
Open
236.64
Day's Range
236.43-239.2
52 wk Range
0-0
Volume
0
Average Vol. (3m)
342,652
1-Year Change
0%
Shares Outstanding
37,163,036
Fair Value
Unlock
Dividends Payment Streak
Unlock
Technical
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Daily
Weekly
Monthly
More
How do you feel today about GEVA?
Vote to see community's results!
or

Synageva BioPharma Corp Company Profile

As of June 19, 2015, Synageva BioPharma Corp. was acquired by Alexion Pharmaceuticals, Inc. Synageva BioPharma Corp. operates as a biopharmaceutical company in the United States. It focuses on the discovery, development, and commercialization of therapeutic products for patients with rare diseases. The company’s lead program include sebelipase alfa, a recombinant form of human lysosomal acid lipase (LAL) under the Kanuma brand name for the treatment of LAL deficiency in infants, children, and adults. It also has various other research programs in various stages of preclinical development, including SBC-103, an enzyme replacement therapy in a Phase 1/2 study for lysosomal storage disease, known as mucopolysaccharidosis type IIIB; SBC-105, an enzyme replacement therapy in preclinical development for rare disorders of calcification; and other programs. The company was founded in 1996 and is headquartered in Lexington, Massachusetts.

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.